New inhaled vaccine delivers broad protection against COVID-19, variants
Editor's Note
In this study, Canadian researchers at McMaster University (Hamilton, Ontario) confirm that their newly developed inhaled form of COVID-19 vaccine provides long-lasting protection against the original strain of SARS-Cov-2 and variants of concern.
The researchers compared two types of adenovirus platforms for the vaccine. The adenoviruses serve as vectors to deliver the vaccine directly into the lungs without causing illness themselves.
Both types were found to be effective against highly transmissible variants because they target three parts of the virus, including two that do not mutate as quickly as the spike protein.
The research, which was initially conducted on animal models, is now being evaluated in healthy adults who have already been vaccinated with two doses of a COVID-19 mRNA vaccine
Because inhaled vaccines target the lungs and upper airways where respiratory viruses first enter the body, they are more effective at inducing a protective immune response, the researchers say.
Free Daily News
- FDA: Surgical mesh mini-slings comparable to mid-urethral slings for stress urinary incontinence
- Federal guidelines require written consent for pelvic exams at hospitals, medical schools
- Survey: More than half of ED nurses experienced violence in past month
- Heart transplant research proves out 24-hour organ preservation method
- Healthcare safety report: Outcomes improving, but workplace violence persists
- Annual CMS rules support underserved, under-resourced communities, promote value-based care
- Data resource details causes, health implications of sleep deprivation
- Medical error initiative from Joint Commission affiliate NQF targets preventable harm, “never events”
- EPA rule to limit dangerous emissions from medical sterilization plants
- Newly FDA-approved microsurgical system holds promise for training, new treatments